After A ‘Solid’ 2022, Amneal Wants To Deliver On Complex Generics And Biosimilars
• By David Wallace
Generate a summary of this article
Listen to this article
With Amneal delivering what it described as a “solid” set of financials for 2022, the company has reaffirmed that it sees more value in moving increasingly into complex generics and bolstering its nascent biosimilars business.
Amneal sees greater value in more complex areas • Source: Shutterstock
Amneal has reported a “solid” set of results for 2022, driving sales up by 6% to $2.21bn as it continues to move into more complex generics and kicks off in earnest its ambitions in biosimilars.
Citing growth from new generics launches as well as the expansion of its AvKare business (Also see "Amneal Takes...
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.